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Nipah  virus  (NiV)  is a  highly  pathogenic,  recently  emerged  paramyxovirus  that has  been  responsible  for





also been  associated  with  recent  outbreaks  in  Malaysia  and  Bangladesh.  Although  over  two  billion people
currently live  in  regions  in  which  NiV  is  endemic  or in which  the Pteropus  fruit bat  reservoir  is  commonly
found,  there  is no  approved  vaccine  to  protect  against  NiV  disease.  This  report  examines  the  feasibility
and  current  efforts  to develop  a NiV vaccine  including  potential  hurdles  for  technical  and  regulatory
assessment  of candidate  vaccines  and  the  likelihood  for ﬁnancing.
© 2016  World  Health  Organization;  licensee  Elsevier  Ltd. This  is  an  open  access  article  under  the  CC
BY  license  (http://creativecommons.org/licenses/by/3.0/).. About the disease and pathogen
Nipah virus (NiV) is a recently emerged highly pathogenic
aramyxovirus of the genus Henipavirus and is the causative agent
f sporadic outbreaks of respiratory and encephalitic disease in
outheast Asia. The World Health Organization (WHO) recently
ublished a concise summary of early knowledge about NiV [1].
iV was ﬁrst recognized as an emerging human pathogen in 1998
uring an outbreak of encephalitic disease among pig farmers in
eninsular Malaysia and Singapore. The Malaysian outbreak was
he result of pig-to-human transmission following an outbreak of
ild respiratory and encephalitic disease in pigs [2]. Human-to-
uman transmission was suspected in a few cases (about 1%). The
ase fatality rate (CFR) for this initial outbreak was  38% in Malaysia
nd Singapore. Pteropus fruit bats were later shown to be the reser-
oir host for NiV. Spillover from bats to pigs likely occurred via
 This is an Open Access article published under the CC BY 3.0 IGO license which
ermits unrestricted use, distribution, and reproduction in any medium, provided
he original work is properly cited. In any use of this article, there should be no
uggestion that WHO  endorses any speciﬁc organisation, products or services. The
se  of the WHO  logo is not permitted. This notice should be preserved along with
he article’s original URL.
∗ Corresponding author at: The University of Texas Medical Branch at Galveston,
ealy Center for Vaccine Development, 301 University Blvd., Galveston, TX 77555-
436, United States. Tel.: +1 409 747 8145; fax: +1 409 747 8150.
E-mail address: gnmillig@utmb.edu (G.N. Milligan).
ttp://dx.doi.org/10.1016/j.vaccine.2015.12.075
264-410X/© 2016 World Health Organization; licensee Elsevier Ltd. This is an open accepartially eaten fruits or direct exposure to infectious bat secretions.
The primary mechanism of exposure to humans in this outbreak
was via infectious secretions from pigs resulting in 276 conﬁrmed
cases and 105 deaths.
While there are no standardized criteria and methodologies,
diagnosis of human infections is based on identiﬁcation of indi-
viduals exhibiting clinical symptoms including altered mental
status and/or seizures. Blood drawn from individuals with sus-
pected NiV infection can be tested for NiV-speciﬁc IgM by ELISA.
PCR-based diagnosis is an alternative method available mainly in
higher income countries [1]. The incubation period is between
4 and 30 days, although most cases range between 5 and 18
days [1,3]. Human cases typically present with abrupt onset of
fever, headache, dizziness, and vomiting. Neurological signs include
reduced levels of consciousness, segmental myoclonus, areﬂexia,
hypotonia, and abnormal doll’s eye-reﬂex which develop in these
individuals within a week of fever onset. In the Malaysia outbreak,
atypical pneumonia was seen in 14% of patients and neurological
symptoms varied among infected individuals. Approximately, 5%
of patients developed late-onset encephalitis ten weeks after infec-
tion which resolved completely while approximately 9% displayed
another round of encephalitis. It is believed that this recurrent
encephalitis is a result of recrudescence due to re-immergence of
a latent infection rather than as a result of a re-infection. There are
currently no known risk factors for relapsed encephalitis [3]. Many
survivors of NiV infection have long-term neurological sequelae
leading to decreased quality of life and earning potential [4].

































































literature including vesicular stomatitis virus (VSV), rabies virus
(RABV), canarypox virus (CNPV ALVAC strain), adeno-associated972 B.A. Satterﬁeld et al. / V
Although no further outbreaks have been reported in Malaysia,
wo outbreaks have occurred in India and nearly annual outbreaks
ave occurred in Bangladesh since 2001. Bangladesh outbreaks
ave been smaller and more isolated than the Malaysia outbreak
ut resulted in higher CFRs (average 75%) with over 300 conﬁrmed
ases from 2001 to 2015. Most outbreaks were clusters of related
ases but occasionally cases of individual infections widely sep-
rated geographically from other NiV cases have been reported.
he clinical presentation is similar to that seen in Malaysia, but
esults in more frequent severe respiratory disease [5] (70% of
ases), and are the result of direct bat-to-human transmission via
onsumption of contaminated raw date palm sap with subsequent
uman-to-human spread. The nature of human-to-human trans-
ission is not clear but requires close contact perhaps mediated
y droplets, fomites, intimate contact with body secretions or a
ombination of these elements. Genomic sequencing showed that
wo distinct NiV strains were responsible for these Malaysia and
angladesh outbreaks. Whether these observed differences in dis-
ase presentation and outcome are due to strain variation, route of
xposure, or differences in healthcare remains to be determined
3]. The two outbreaks in Indian regions bordering Bangladesh
esulted in similar CFR and were also likely transmitted via con-
umption of contaminated date palm sap. Recently, a henipavirus,
ost likely NiV, caused an outbreak in the Philippines with 17 cases
nd nine fatalities. Human infections occurred following exposure
o infected horses, possible human-to-human transmission (likely
ia close contact), and transmission to domestic cats and a dog
as also reported [6]. Due to poor surveillance in rural areas of
ountries with endemic NiV, the true disease burden is uncertain
nd many cases likely go undetected. The outbreaks in Malaysia,
angladesh, India, and the Philippines involved the loss of life and
iminished the earning potential of survivors due to long-term dis-
bility demonstrating a clear economic impact of the NiV outbreaks.
ecause NiV is highly infectious to humans by aerosols, and is life-
hreatening to humans and agricultural animals with a high CFR,
iV is classiﬁed internationally as a biosafety level 4 (BSL4 or P4)
gent [7].
Several risk factors have led to the proposal that NiV poses a
andemic threat including: a broad host range, widespread distri-
ution of the predominant Pteropus bat reservoir as well as less
ominant Eonycteris,  Cynopterus, Scotophilus,  and Hipposideros bat
eservoirs across Southern Asia, Australia, and Madagascar, and
igh seroprevalence rates in reservoirs. Antibodies against henipa-
ike viruses have also been discovered in Eidolon helvum bats [8]
nd domestic pigs [9] in Ghana as well as in humans reporting
ontact with bats in Cameroon [10]. In addition, over half of cases
n Bangladesh are due to human-to-human transmission [11]. As
emonstrated by the recent West African Ebola outbreak, there is
otential for highly pathogenic emerging infections that normally
ause only small, isolated and containable outbreaks to occasion-
lly result in large epidemics that inﬂict a signiﬁcant mortality
nd morbidity burden. In this regard, the number of people at risk
f acquiring NiV in Bangladesh and the neighboring West Bengal
tate of India (regions that experience more frequent outbreaks)
xceeds 250 million. The total number of people at risk, includ-
ng all countries that experience NiV outbreaks and in which the
teropus bats occur naturally, exceeds two billion.
Despite the potential importance of NiV as an emerging dis-
ase pathogen, no speciﬁc therapeutics or vaccines are currently
pproved for use in humans. Current prevention of disease in
ndemic countries relies on behavior modiﬁcations to prevent
pillover, including farming practices which decrease livestock
xposure to bats, the use of bamboo skirts to prevent date palm
ap contamination, and pasteurizing date palm sap. Though these
pproaches appear to be effective strategies of prevention, their
mplementation is often problematic due to cultural factors [12]. 34 (2016) 2971–2975
2. Overview of current efforts
2.1. Biological feasibility for vaccine development
Although no licensed human vaccines for NiV exist, there is
strong evidence that an effective vaccine is feasible. Other related
paramyxoviruses, such as measles virus (MV) and mumps virus,
yield long-term immunity after natural infection, and safe, efﬁca-
cious live attenuated vaccines with deﬁned correlates of protection
have been developed that have been used safely against these
pathogens for decades. Recent evidence also suggests that almost
all successful viral vaccines target viruses with average incubation
periods of at least 5–7 days whereas efforts have proved largely
unsuccessful to produce vaccines for viruses with shorter incuba-
tion periods [13]. The evidence suggests that the average incubation
period for NiV is above the 5–7 day threshold and therefore has
strong potential for the development of a successful vaccine. Addi-
tionally, various candidate vaccine platforms have demonstrated
the feasibility of using one or both of the NiV outer-membrane pro-
teins, the glycoprotein (G) and fusion (F) protein, as the antigen(s)
to stimulate a protective immune response in various preclincal
challenge models including hamsters [14,15], cats [16], ferrets [17],
African green monkeys (AGMs) [18,19], and pigs [20]. Neutralizing
antibody titers typically ranging from about 160 to 16,000 were
induced in several animal models by these vaccines. Little or no
clinical signs of disease were observed in vaccinated animals after
NiV challenge and protection against mortality was typically 100%
depending on the vaccination route and dose. Immune responses
are also produced in mice, although mice are not susceptible to
NiV infection and therefore protection could not be assessed [21].
The nature of the protective immunity provided by immunization
with these vaccine antigens is not completely deﬁned but likely due
to inhibitory/neutralizing antibodies that prevent binding and/or
fusion of NiV with host cells. This mechanism would be consis-
tent with the ability of various polyclonal or monoclonal antibodies
against the NiV or HeV F and/or G proteins to protect in animal
models when administered either pre- or post-exposure [22,23].
Due to the extreme lethal nature of NiV, producing a safe, live
attenuated vaccine with no potential of reversion is generally con-
sidered a difﬁcult approach, although recombinant-derived NiV
mutants have been produced that are attenuated in hamster and
ferret models and generate a strong neutralizing antibody response
[24,25]. Most candidate vaccine platforms have either focused
on the subunit vaccine or live-vectored vaccine approaches. It
is notable that there are no current vaccine candidates using
formalin-inactivated NiV, likely due to the safety issues that have
arisen in the past with formalin-inactivated paramyxovirus vac-
cines including early attempts with MV  [26,27] and respiratory
syncytial virus vaccine development [28,29]. The most studied
vaccine candidate is a subunit vaccine consisting of a soluble gly-
coprotein (sG) from the related henipavirus Hendra virus (HeV),
which causes human and equine disease. HeV and the NiV Malaysia
strain share amino acid homology between all viral proteins of
between 68 and 92%. For the F protein, the homology is 88% whereas
there is a homology of 83% for the G protein [30]. This HeV sG vac-
cine also protects ferrets and AGMs from experimental challenge
with NiV as well as HeV. One formulation of this HeV sG vac-
cine called Equivac® HeV, has recently been licensed to vaccinate
horses in Australia against HeV, thus demonstrating the feasibility
of henipavirus vaccine development [23]. The characteristics and
formulation of this vaccine will be described in Section 3.
Various vectored vaccine candidates have been described in thevirus (AAV), MV,  Newcastle disease virus (NDV), and Venezuelan
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ased on current vaccine strains of these viruses with known safety
roﬁles. Ebola vaccine candidates utilizing a VSV vector similar
o the strategy for NiV are currently in advanced clinical evalu-
tion [31–33]; their safety and efﬁcacy data will help determine
he feasibility of utilizing the VSV vaccine platform for NiV vac-
ines. Research to date has focused on two strains of NiV: the
alaysia (NiVM) and Bangladesh (NiVB) strains. These strains share
5% amino acid homology in the G protein and 98% homology in the
 protein. Although they share even less homology with the G and
 proteins of HeV, several studies have shown signiﬁcant or com-
lete cross-protection with vaccines for NiVM, NiVB, and HeV. The
urability of protection for the various vaccine candidates has not
et been assessed with the exception of a single study showing the
eV sG vaccine conferring protection against NiV at least 12 months
fter two vaccinations administered 20 days apart in ferrets [34].
Monoclonal antibodies targeting the surface glycoproteins of
eV have shown efﬁcacy against both HeV and NiV as pre- and
ost-exposure prophylaxis in animal models [35] but since these
ntibodies must be administered before the onset of clinical signs,
hey are unlikely to be useful for treating symptomatic patients in
n outbreak scenario, but may  prove beneﬁcial in prophylactically
reating potentially exposed individuals. In this regard, a human-
zed monoclonal antibody speciﬁc for the Hendra G protein and
ross-reactive with the related G protein of NiV has been used as
 therapeutic treatment in ten humans with signiﬁcant exposure
isk to HeV or NiV [36].
.2. General approaches to vaccine development for this disease
or low and middle income country markets
Age does not appear to be a factor in NiV disease as documented
nfections have occurred in individuals from all age groups and no
ifference in disease severity has been observed among different
ge groups. The only country with regular, recurring outbreaks at
he present time is Bangladesh, thus that population is likely in
reatest need of a NiV vaccine. However, seropositive Pteropus bats
ave been detected throughout much of Southeast Asia and pose
otential for risk of NiV outbreaks to further human populations.
NiV outbreaks have been associated with infection of pigs or
orses with subsequent spread to human populations, although the
nnual outbreaks in Bangladesh are not associated with domes-
ic livestock, but direct contamination from infected fruit bats
nd human-to-human transmission. Some vaccination strategies
nclude vaccinating swine herds or horses to prevent spread to
uman populations; however, this strategy would not pertain to
angladesh, and potentially other countries where human vacci-
ation is needed to prevent disease.
Several vaccination strategies for direct protection of humans
re possible but are highly inﬂuenced by the unpredictable occur-
ence of NiV outbreaks and the limited number of cases typically
ound in an average NiV outbreak. One strategy would deploy a
tockpiled vaccine for ring vaccination around a village or area
here NiV cases are discovered similar to that examined in the
urrent Ebola outbreak [32]. Other possible approaches involve cre-
ting vectored vaccines capable of protecting against both NiV and
ther pathogens such as MV  or RABV in order to reduce the costs
nd ease the logistics of delivering this vaccine.
. Technical and regulatory assessment
No clinical trials have yet begun for NiV vaccine candidates. The
pidemiology and sporadic nature of NiV outbreaks makes large
cale, Phase III clinical trials difﬁcult to plan to assure achieving
eaningful efﬁcacy results that would support licensure. A path-
ay for approval might be possible in the United States via the 34 (2016) 2971–2975 2973
Food and Drug Administration’s (FDA) Animal Rule or through
the identiﬁcation of surrogate markers of immune protection. The
FDA’s Animal Rule is intended to enable approval of drugs against
highly lethal infections in situations where deﬁnitive human efﬁ-
cacy studies cannot be conducted because it would be unethical,
and/or ﬁeld trials have not been feasible. In this instance, efﬁcacy
via protection in one or two experimental animal models that repli-
cate key characteristics of the human disease and are predictive
of the mechanism of protection in humans may  offer an alterna-
tive licensure pathway. The AGM, ferret, and hamster models are
well established and accurately model human disease. Further-
more, the sG and VSV vaccines have protected AGMs and ferrets
from lethal intranasal and intratracheal NiV challenge. However,
although this mechanism may  represent a potential pathway for
NiV vaccine approval in the United States, no vaccines have been
approved through this mechanism to date. Even with the Animal
Rule, human Phase I/II trials will still be required for safety trials,
and having these conducted before the beginning of a large-scale
outbreak is important in allowing for a rapid response. The lack
of these trials prior to the current Ebola outbreak has been a hin-
drance in the rapidity of deploying a vaccine in a timely manner
[31–33].
Identiﬁcation of an accurate correlate or surrogate of protec-
tion might serve as a satisfactory vaccination outcome to facilitate
regulatory approval, although true correlates of protection against
NiV are not completely deﬁned and standardized methods for mea-
suring immune correlates are currently lacking. The correlate of
protection against NiV infection of humans will likely involve neu-
tralizing antibody levels [37]. Neutralizing antibodies appear to be
a main mediator of protection as evidenced by the ability of the
several vaccine candidates to induce neutralizing antibodies, and
by the protective role of passive antibody transfer in experimen-
tal animal models. The sG vaccine animal efﬁcacy data suggests
that neutralizing antibody titers as low as 16 or 32 offer full pro-
tection against NiV and HeV [37] but we do not know how this
level of neutralizing activity translates to protection in humans.
The necessity of performing neutralization assays with virulent NiV
under conditions of high biocontainment complicates development
of neutralization assays using standardized reagents, NiV strains,
and assay conditions. More importantly, this issue precludes com-
mon  use of these assays in most basic and clinical laboratories. The
use of pseudotype viruses in neutralization assays may  overcome
assay development and standardization gaps by allowing assays
to be performed under biosafety levels attained in most basic and
clinical laboratories [38]. As an alternative approach, identiﬁca-
tion and quantiﬁcation of potential non-neutralizing, serological
surrogate markers of vaccine protection may involve the use of
multiplexed microsphere assays or ELISA assays for quantiﬁca-
tion of NiV-speciﬁc IgG, IgA, and IgM responses. However, further
work is needed to standardize reagents and assay conditions and
to deﬁne any relationship between speciﬁc antibody levels and
immune protection [18].
Most candidate NiV vaccines are in early stages of develop-
ment. Experimental vaccines in which NiV proteins are expressed
by various virus vectors represent an attractive approach in NiV
vaccine development. VSV-vectored Ebola vaccines are currently
in Phase III efﬁcacy trials [32], suggesting that a similar safety and
efﬁcacy testing pathway might be implemented for VSV vectored
NiV vaccines. However, as mentioned previously, a subunit vaccine
called Equivac HeV® incorporating sG is already in production as an
approved veterinary vaccine for HeV in Australia [37]. This vaccine
is formulated using 100 g of sG prepared from either 293F human
embryonic kidney or CHO cells with a proprietary immunostim-
ulatory complex adjuvant. Currently, the vaccine is administered
to horses by the intramuscular route as two immunizations, three
to six weeks apart followed by boosting at six month intervals.
2974 B.A. Satterﬁeld et al. / Vaccine
Table 1





HeV sG X Zoetis, Inc./USU [16,18,34,39]
Vectored vaccines
VSV-NiVB F and/or G X UTMB [17]
VSV-NiVM G X CDC [15]
VSV-NiVM G X RML  [14,19]
VSV-NiVM F and/or G X Yale University [40]
VSV-HeV G: X TJU/RML [41]
RABV-HeV G: X TJU/RML [41]
ALVAC-F/G X CFIA-NCFAD [20,42]
AAV-NiVM G X INSERM [43]
rMV-Ed-G X UoT [44]





Polyclonal serum NiV F
or G
X INSERM [46]
Mouse mAbs NiV F or G X INSERM [47]
Human mAb  m102.4
Henipah G
X USU [35,48]
Abbreviations:  USU (Uniformed Services University of the Health Sciences); UTMB
(University of Texas Medical Branch); CDC (Centers for Disease Control and Pre-
vention); RML  (Rocky Mountain Laboratories); TJU (Thomas Jefferson University);



































yases); Institut national de la santé et de la recherché médicale (INSERM); UoT
University of Tokyo); CAAS-SKLVB (Chinese Academy of Agricultural Sciences
CAAS) – State Key Laboratory of Veterinary Biotechnology (SKLVB)).
he success of experimental sG vaccines in experimental animal
odels and the use of Equivac HeV® as an effective vaccine in
orses suggest this approach may  also be efﬁcacious in humans.
ormulation of sG with an approved adjuvant represents a plat-
orm that should likely be investigated through human clinical
tudies.
. Status of vaccine R&D activities
All R&D activities for NiV vaccines are in the pre-clinical stage
aving been tested in the hamster, ferret, and/or AGM preclinical
hallenge models. Table 1 provides a summarized list of cur-
ent preclinical vaccine candidates. Various experimental subunit
accines utilizing sG protein and adjuvants such as Alhydrogel®
nd CpG oligodeoxynucleotide have been shown to be protective
gainst NiV in multiple animal models. The most advanced vaccine
f this category is Equivac HeV® that is formulated with a propri-
tary immunostimulatory complex adjuvant. The sG vaccine has
een shown to be cross-protective between NiVM and HeV. There
re other various vectored vaccine candidates that have been tested
n animal models. Of these, the most studied by multiple groups is
he VSV vector using a similar strategy to that being employed in
bola virus vaccine candidates in current clinical trials, however
he VSV vector used is not identical among studies. Additional vac-
ine vectors include RABV, CNPV ALVAC, AAV, MV,  VEE, and NDV.
ll of these candidate vaccines utilize the NiV outer-membrane G
nd/or F proteins as target antigens to elicit neutralizing antibod-
es and give full protection in hamster [15], ferret [17], or AGM [19]
odels after a single injection without the use of adjuvants. A VSV-
ectored vaccine has been shown to be cross-protective between
iVB and NiVM [17]. The remaining cross-protection studies have
ot been performed or published. Passive antibodies to NiV or HeV and/or F have also been demonstrated to give protection against
iV [22].
Almost all published results have occurred within the last ﬁve
ears and are preliminary studies with small numbers of animals,
[ 34 (2016) 2971–2975
and all of these candidates are from academic laboratories (Uni-
formed Services University of the Health Sciences [USU], University
of Texas Medical Branch [UTMB], Yale University, Thomas Jefferson
University [TJU], and University of Tokyo [UoT]) or government
(United States [US] Centers for Disease Control and Prevention
[CDC], Rocky Mountain Laboratories [RML], Canadian Food Inspec-
tion Agency [CFIA] National Center for Foreign Animal Diseases
[NCFAD], Institut national de la santé et de la recherche médicale
[INSERM], and Chinese Academy of Agricultural Sciences [CAAS]
State Key Laboratory of Veterinary Biotechnology [SKLVB]), with
the HeV sG vaccine also having vaccine pharma partners (e.g. Pﬁzer
Animal Health, and Zoetis, Inc.).
5. Likelihood for ﬁnancing
An effective NiV vaccine would likely ﬁnd use primarily in
the low and middle income countries where the virus is cur-
rently endemic. Vaccine ﬁnancing could potentially be made
available through mechanisms such as The Gates Foundation or
Gavi, although there are potential impediments to this approach.
Bangladesh and India are currently Gavi-eligible but other NiV-
endemic countries such as Malaysia and the Philippines are not. Due
to the current low incidence of disease and relatively early develop-
ment status of vaccine candidates, it is unlikely that NiV vaccines
would be selected for funding from these types of programs as a
general childhood vaccine unless the vaccine was coupled with
another, more common vaccine such as for MV.  A non-coupled
NiV vaccine for use primarily as a traveler’s vaccine or for immu-
nization of military recruits would likely have to be developed
and funded by universities with government and eventual pharma-
ceutical partnering, in a similar fashion to the current Ebola virus
vaccine candidates.
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